SecSonar.com

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Inovio Pharmaceuticals, Inc. (INO) is a Biotechnology company based in US with a market capitalization of $71M. Revenue declined 70.0% year-over-year and free cash flow was negative at -$88.9M. This page tracks INO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 134 employees · IPO Dec 8, 1998

Valuation

Valuation & price

$1.30 · as of May 17, 2026 · -54.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.95

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.79$1.92$1.05Jul 25Dec 25Jul 26Jul 7, 25$1.33Jul 9, 25$1.45Jul 11, 25$1.36Jul 15, 25$1.31Jul 17, 25$1.37Jul 21, 25$1.42Jul 23, 25$1.56Jul 25, 25$1.47Jul 29, 25$1.43Jul 31, 25$1.42Aug 4, 25$1.47Aug 6, 25$1.46Aug 11, 25$1.44Aug 13, 25$1.70Aug 15, 25$1.86Aug 19, 25$1.94Aug 21, 25$1.91Aug 25, 25$1.95Aug 27, 25$2.46Aug 29, 25$2.37Sep 3, 25$2.71Sep 5, 25$2.79Sep 9, 25$2.75Sep 11, 25$2.65Sep 16, 25$2.28Sep 18, 25$2.31Sep 22, 25$2.49Sep 24, 25$2.52Sep 26, 25$2.48Sep 30, 25$2.34Oct 2, 25$2.46Oct 6, 25$2.41Oct 8, 25$2.56Oct 10, 25$2.57Oct 14, 25$2.44Oct 16, 25$2.46Oct 21, 25$2.33Oct 23, 25$2.25Oct 27, 25$2.49Oct 29, 25$2.43Oct 31, 25$2.35Nov 4, 25$2.43Nov 6, 25$2.25Nov 10, 25$2.15Nov 12, 25$1.96Nov 14, 25$2.05Nov 18, 25$1.89Nov 20, 25$1.73Nov 25, 25$1.81Nov 28, 25$2.06Dec 2, 25$1.92Dec 4, 25$2.02Dec 8, 25$2.09Dec 10, 25$2.17Dec 12, 25$2.06Dec 16, 25$2.32Dec 18, 25$2.37Dec 22, 25$2.25Dec 24, 25$2.25Dec 29, 25$1.73Jan 2, 26$1.69Jan 6, 26$1.60Jan 8, 26$1.61Jan 12, 26$1.54Jan 14, 26$1.64Jan 16, 26$1.52Jan 21, 26$1.51Jan 23, 26$1.51Jan 27, 26$1.53Jan 29, 26$1.61Feb 2, 26$1.70Feb 4, 26$1.67Feb 9, 26$1.69Feb 11, 26$1.61Feb 13, 26$1.61Feb 18, 26$1.67Feb 20, 26$1.73Feb 24, 26$1.89Feb 26, 26$1.79Mar 2, 26$1.74Mar 4, 26$1.73Mar 6, 26$1.74Mar 10, 26$1.73Mar 12, 26$1.68Mar 17, 26$1.68Mar 19, 26$1.65Mar 23, 26$1.61Mar 25, 26$1.54Mar 27, 26$1.61Mar 31, 26$1.74Apr 2, 26$1.13Apr 7, 26$1.05Apr 9, 26$1.05Apr 13, 26$1.09Apr 15, 26$1.19Apr 17, 26$1.19Apr 22, 26$1.14Apr 24, 26$1.15Apr 28, 26$1.15Apr 30, 26$1.12May 4, 26$1.14May 6, 26$1.24May 8, 26$1.46May 12, 26$1.41May 14, 26$1.36May 18, 26$1.22May 20, 26$1.23May 22, 26$1.35May 28, 26$1.30Jun 1, 26$1.28Jun 3, 26$1.14Jun 5, 26$1.07Jun 9, 26$1.10Jun 11, 26$1.10Jun 15, 26$1.10Jun 17, 26$1.11Jun 22, 26$1.11Jun 24, 26$1.10Jun 26, 26$1.10Jul 2, 26$1.22
$1.0552-week range$2.87
Loading valuation history…

Fundamentals

Key fundamentals

$71M

Market cap

-70.0%

Revenue growth (YoY)

100.0%

Gross margin

-$88.9M

Free cash flow (USD)

-$49.1M

Net debt

Net cash position

1626.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$35.4MFY 2017$42.2MFY 2018$30.5MFY 2019$4.1MFY 2020$7.4MFY 2021$1.8MFY 2022$10.3MFY 2023$832.0KFY 2024$217.8KFY 2025$65.3K
$35.4M$65.3K

Free cash flow by year

2016 → 2025

FY 2016$-66.5MFY 2017$-73.5MFY 2018$-75.6MFY 2019$-98.8MFY 2020$-179.5MFY 2021$-216.9MFY 2022$-217.2MFY 2023$-124.7MFY 2024$-104.6MFY 2025$-88.9M
-$66.5M-$88.9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • FinancingSecurities RegistrationJul 2, 2026Filing
  • 8-K eventBylaws AmendmentMay 20, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • 8-K eventPublic Offering AnnouncedApr 6, 2026Filing
  • 8-K eventATM Prospectus TerminationApr 2, 2026Filing

Questions

Frequently asked questions

What is Inovio Pharmaceuticals, Inc.'s market cap?

Inovio Pharmaceuticals, Inc. (INO) has a market capitalization of $71M.

What is INO's P/E ratio?

A meaningful P/E ratio is not available for INO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is INO's price-to-book (P/B) ratio?

INO trades at 2.95 times book value per share.

Are insiders buying INO stock?

SEC Form 4 filings show no open-market insider buys at Inovio Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

MCRB

Seres Therapeutics, Inc.

$73.1M

SPRB

Spruce Biosciences, Inc.

$68.2M

CLNN

Clene Inc.

$67.7M

TCRX

TScan Therapeutics, Inc.

$67.2M

CBUS

Cibus, Inc.

$66.6M

MNOV

MediciNova, Inc.

$66M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.